Physician profile

John C Welch

Family Medicine · Vestal, NY

NPI 1750510848

$504.34

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$45.71

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $181.28 2021-2023 Vraylar
Astellas Pharma US INC $134.66 2019
Lilly USA, LLC $39.53 2019
Novo Nordisk INC $26.15 2019
Amarin Pharma, INC. $23.16 2019
Janssen Biotech, INC. $17.83 2024 Tremfya
Janssen Pharmaceuticals, INC $16.69 2019
Allergan, INC. $14.79 2019
Glaxosmithkline, LLC. $13.94 2019
Boehringer Ingelheim Pharmaceuticals, INC. $12.73 2019
Pfizer INC. $12.61 2019
Astrazeneca Pharmaceuticals LP $10.97 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John C Welch

$504.34

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/351682/john-c-welch

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.